QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 0.003
-- x --
-- x --
-- - --
$ 0.00 - $ 1.69
23,866
na
7.9M
$ 1.44
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-14-2024 09-30-2024 10-Q
2 08-06-2024 06-30-2024 10-Q
3 05-06-2024 03-31-2024 10-Q
4 03-28-2024 12-31-2023 10-K
5 11-09-2023 09-30-2023 10-Q
6 08-03-2023 06-30-2023 10-Q
7 05-04-2023 03-31-2023 10-Q
8 03-01-2023 12-31-2022 10-K
9 11-08-2022 09-30-2022 10-Q
10 08-04-2022 06-30-2022 10-Q
11 05-04-2022 03-31-2022 10-Q
12 03-10-2022 12-31-2021 10-K
13 11-10-2021 09-30-2021 10-Q
14 09-10-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 omega-therapeutics-restructuring-committee-approved-workforce-reduction-of-up-to-17-employees-for-cost-reduction-amid-chapter-11-case-and-potential-asset-sale

https://www.sec.gov/ix?doc=/Archives/edgar/data/1850838/000119312525019359/d927659d8k.htm On February 3, 2025, the Company, wit...

 omega-therapeutics-receives-default-notice-from-banc-of-california-disputes-alleged-breach-of-loan-terms-bank-sets-off-1467m-deposits-maintains-compliance-claims-seeks-resolution

On January 13, 2025, Omega Therapeutics, Inc. (the "Company") received a notice of default (the "Notice of Default&...

 omega-therapeutics-receives-non-binding-proposal-from-mirai-bio-to-modify-terms-of-research-collaboration-agreement-with-novo-nordisk-and-pioneering-medicines-08---filing

Under the terms of the Proposal, Mirai would acquire all of the Company's rights and obligations under the Collaboration Ag...

 piper-sandler-maintains-overweight-on-omega-therapeutics-lowers-price-target-to-4

Piper Sandler analyst Edward Tenthoff maintains Omega Therapeutics (NASDAQ:OMGA) with a Overweight and lowers the price targ...

 omega-therapeutics-q3-2024-gaap-eps-030-misses-028-estimate-sales-2612m-beat-1240m-estimate

Omega Therapeutics (NASDAQ:OMGA) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of ...

 omega-therapeutics-completes-phase-1-mychelangelo-i-clinical-trial-and-a-strategic-prioritization-of-its-pipeline

Established clinical proof-of-mechanism and validation of epigenomic controllers as potential new class of medicines from compl...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION